|
**Overview**: Congenital Hypothyroidism Confirmatory Panel**Introduction**: The Congenital Hypothyroidism Confirmatory Panel is a diagnostic tool designed to confirm congenital hypothyroidism using serum samples. In India, congenital hypothyroidism (CH) is one of the most common preventable causes of intellectual disability (prevalence 1 in 1,130â€"2,800 live births per NBS programs), higher than global averages due to iodine deficiency in some regions despite universal salt iodization. Early detection and levothyroxine replacement prevent irreversible neurodevelopmental damage. High morbidity from underdiagnosis or delayed confirmation in rural/low-SES newborns, limited NBS follow-up, delayed treatment leading to cretinism or poor cognitive outcomes. Per endocrinology practices aligned with ICMR, AAP, and Indian Society for Pediatric and Adolescent Endocrinology guidelines, the test employs immunoassay for TSH and free T4 over 1-2 days with high sensitivity/specificity, valuable as confirmatory after NBS screening. This diagnostic falls under thyroid screening and targets newborns with elevated TSH on screening or clinical suspicion (prolonged jaundice, lethargy, constipation, umbilical hernia), addressing accurate confirmation to initiate lifelong therapy and parental counseling. With elevated morbidity due to delayed confirmation, the test supports public health efforts by enabling precise diagnosis, facilitating early intervention, and reducing preventable intellectual disability. Its serum-based approach ensures reliable performance in India's expanding NBS programs.**Other Names**: Hypothyroid Pnl.**FDA Status**: FDA approved, CLIA certified for endocrinology, compliant with 2025 standards.**Historical Milestone**: NBS for CH implemented; in India, confirmatory testing key in national programs.**Purpose**: The test confirms 2 parameters including TSH and free T4 to guide congenital hypothyroidism diagnosis, assess thyroid function, inform levothyroxine therapy.**Test Parameters**: 1. TSH, 2. Free T4.**Pretest Condition**: No fasting required; newborns should have positive NBS or clinical signs.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Parents should provide details on NBS results, newborn symptoms (jaundice, poor feeding, lethargy), family thyroid history.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated CH including intellectual disability, benefits of early confirmation, and minimal discomfort from venipuncture.**Procedural Considerations**: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store kits according to manufacturer specifications to ensure reliability.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis, or maternal thyroid antibodies can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Elevated TSH with low free T4 confirms CH, necessitating immediate therapy. Normal may require follow-up if NBS positive.**Specialist Consultation**: Pediatric endocrinologists should be consulted for management.**Additional Supporting Tests**: Thyroid ultrasound, bone age for confirmation.**Test Limitations**: Transient elevations possible; comprehensive approach required.**References**: Indian Journal of Pediatrics 2024, NBS CH Studies India 2023. |
